VEGFA and head and neck squamous cell carcinoma: As reported by Argiris et al. [22,32], or demonstrated by ASCO 2020 through the presentation of the LEAP-010 study, evaluating the efficacy of lenvantinib in combination with pembrolizumab in patients with HNSCC [44], targeting the VEGF pathway, remains of interest.